Vericel (VCEL) Growth Rates Comparisons to Biotechnology & Pharmaceuticals Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Customers, else..
 
Vericel Corporation  (NASDAQ: VCEL)
 

Vericel Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VCEL Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) 22.48 % 5.15 % 8.96 % 10.9 %
Q / Q Revenue Growth (Q2 MRQ) 13.2 % -11.92 % -3.29 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 22.95 % 5.66 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) 4.87 % 1.16 % 2.03 % 2.61 %
Revenue 5 Year Average Growth 17.34 % 8.2 % 8.65 % 10.59 %


VCEL's Growth Comparisons in II. Quarter 2026




Strong but slowing Revenue rise by Vericel of 22.48% year on year , in the second quarter 2026 to 77 millions, was higher than the 5.15% growth in the Biotechnology & Pharmaceuticals industry, and 8.96% growth in the Healthcare sector. Despite modest Sales rises in the Healthcare sector and in the Biotechnology & Pharmaceuticals industry, Vericel Corporation reported above average market Sales growth.

Top-line improved by 13.2% from the first quarter. Looking into annual sales rise of 17.34%, and S & P 500's average yearly sales growth is 10.59% over the five years, including only Businesses with the second quarter 2026 Results. Vericel grew faster than the market.

VCEL Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Time-and-materials contract MACI implants kits and instruments Time-and-materials contract
109.28 %
0 %
Directly to consumer Biopsy kits
-5.61 %
0 %
M A C I Implants and kits
5.5 %
0 %
Directly to consumer Epicel
26.36 %
0 %
Total
22.48 %
13.2 %


Growth Rates of VCEL's Income in the second quarter 2026


VCEL Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) - 434.95 % 4.74 % 97.6 %
Sequential Operating Income Change (Q2 MRQ) - -48.89 % 1.4 % 48.13 %
Y / Y Operating Income Growth (Q2 TTM) 1428.5 % 954.66 % 30.73 % 40.67 %
Sequential Operating Income Growth (Q2 TTM) 15.62 % 230.06 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change - -18.41 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) - -78.96 % -26.27 % 90.69 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) - - -66.19 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) 240.8 % -86.66 % 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q2 TTM) 12.86 % -59.21 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - -11.5 % 0.17 % -28.52 %

VCEL Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) - -78.9 % -26.24 % 90.69 %
Q / Q Net Income Growth (Q2 MRQ) - -86.69 % -1.54 % 27.07 %
Y / Y Net Income Change (Q2 TTM) 240.8 % 103.06 % 15.51 % 57.33 %
Sequential Net Income Change (Q2 TTM) 12.86 % -7.95 % -6.72 % 18.65 %
Net Income 5 Year Avg. Growth - -8.55 % 9.21 % 22.96 %

VCEL's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) - -82.2 % -26.27 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) - - -66.19 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) 219.58 % - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) 11.65 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth 40.63 % 49.32 % 0.17 % -28.52 %



VCEL EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) - -82.15 % -26.24 % -28.52 %
Q / Q EPS Net Growth (Q2 MRQ) - -88.25 % -1.54 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) 11.9 % - - 4.93 %
EPS Net 5 Year Avg. Change - -8.55 % 9.21 % 22.96 %



Vericel reported bottom-line of $ 0.04 in the second quarter, compare to $ -0.01 in the same quarter a year ago. Biotechnology & Pharmaceuticals industry fell by -82.15%, while Healthcare sector decreased by -26.24%, and overall market improved by 90.69%.

The bottom-line improved by 13.2% from the first quarter. Looking into annual income per share rise of 17.34%, and S & P 500's average yearly income per share growth is 22.96% over the five years, including only Businesses with the second quarter 2026 earnings reports. Vericel grew less than the market.

VCEL Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) 17503.7 % 6160.46 % 49.73 % 48.62 %
Sequential Free Cash Flow Change (Q2 MRQ) -5.73 % -53.57 % -47.17 % 34.18 %
Y / Y Free Cash Flow Change (Q2 TTM) - 14 % 18.71 % 60.27 %
Sequential Free Cash Flow Change (Q2 TTM) 29.86 % 16.85 % 5.44 % 15.75 %
Free Cash Flow 5 Year Avg. Change 10.61 % -14.51 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q2 MRQ) - 36.63 % - 216.68 %
Y / Y Net Cash Flow Change (Q2 TTM) 514.86 % 784.84 % - 209.43 %
Sequential Net Cash Flow Change (Q2 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change 17.03 % 23.25 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) -76.24 % 32.26 % 8.24 % 120.03 %
Sequential Capital Expenditures Change (Q2 MRQ) 53.7 % -1.95 % -21.55 % 36.87 %
Y / Y Capital Expenditures Change (Q2 TTM) -85.59 % -4.97 % 7.86 % 109.38 %
Sequential Capital Expenditures Change (Q2 TTM) -43.65 % 8.05 % 1.62 % 23.05 %
Capital Expenditures 5 Year Avg. Change 59.56 % 9.64 % 9.09 % 14.54 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.